Impressum

Complication of pernicious anemia during interferon-β treatment for type C chronic hepatitis.

Sat, 14 Apr 2012 13:06:00 +0200

Rinsho Ketsueki. 2012 Mar;53(3):352-6.
Ichihara H, Koh S, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Terada Y, Yamane T, Hino M, Mugitani A.
Department of Hematology, Fuchu-Hospital.

A 62-year-old man with chronic hepatitis C underwent interferon (IFN)-β therapy. After treatment for a period comprising 29 months and 2 weeks, hematological results showed a decrease in white blood cell, hemoglobin, and platelet counts (WBC 2,300/�l, Hb 7.2g/dl, PLT 4.7�10(4)/�l), and IFN therapy was stopped.

Despite therapy discontinuation, the pancytopenia continued to progress with elevation of LDH (LDH 4,898IU/l), and the patient was admitted

Diabetes, hepatitis virus infection and hepatocellular carcinoma: A case-control study in hepatitis endemic area.

Wed, 04 Apr 2012 12:39:00 +0200

Hepatol Res. 2012 Feb 29. doi: 10.1111/j.1872-034X.2012.00979.x. [Epub ahead of print]
Ko WH, Chiu SY, Yang KC, Chen HH.
Division of Gastroenterology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital College of Medicine, Taipei Medical University Division of Biostatistics, Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei Department of Health Care Management, College of Management, Chang Gung University, Tao-Yuan, Taiwan.

Aim:
In spite of numerous studies on the association between diabetes mellitus (DM) and hepatocellular carcinoma (HCC), the results

HCV: Written in our DNA.

Wed, 22 Feb 2012 16:08:00 +0100

Self Nonself. 2011 Apr;2(2):108-113. Epub 2011 Apr 1.
Kanduc D.
Department of Biochemistry and Molecular Biology; University of Bari; Bari, Italy.

An inspection of the sequence similarity between the hepatitis C virus (HCV) polyprotein and human proteins revealed a high level of peptide sharing, with a limited number of motifs unique to the virus (i.e., with no counterpart in the human proteome).

Using pentapeptide matching, only 214 motifs out of a total of 3,007 (7.11%) identified HCV as nonself compared to the Homo sapiens proteome.

However, this virus-versus-human phenetic difference disappeared

Exploitation of lipid components by viral and host proteins for hepatitis C virus infection.

Wed, 22 Feb 2012 15:42:00 +0100

Front Microbiol. 2012;3:54. Epub 2012 Feb 14.
Moriishi K, Matsuura Y.
Department of Microbiology, Faculty of Medicine, University of Yamanashi Chuo-shi, Yamanashi, Japan.

Hepatitis C virus (HCV), which is a major causative agent of blood-borne hepatitis, has chronically infected about 170 million individuals worldwide and leads to chronic infection, resulting in development of steatosis, cirrhosis, and eventually hepatocellular carcinoma. Hepatocellular carcinoma associated with HCV infection is not only caused by chronic inflammation, but also by the biological activity of HCV proteins.

HCV core protein is known as a main component

A case of NMO (neuromyelitis optica) spectum disorder triggered by interferon alpha, which involved extensive pyramidal tract lesion of the brain.

Fri, 27 Jan 2012 10:30:00 +0100

Rinsho Shinkeigaku. 2012 Jan;52(1):19-24.
Yamasaki M, Matsumoto K, Takahashi Y, Nakanishi H, Kawai Y, Miyamura M.
Department of Neurology, Ise Municipal General Hospital.

A 65-year-old woman developed left optic neuritis during the course of peg-interferon alpha (PEG-IFN-α) and ribavirin combination therapy for chronic hepatitis C.

Brain T(2)W-MRI disclosed hyperintense lesions in the corpus callosum and white matter. We diagnosed neuromyelitis optica spectrum disorder (NMOSD) on the basis of anti-aquaporin-4 antibody seropositivity. PEG-IFN-α was discontinued, and she received steroid pulse therapy (intravenous high dose methylprednisolone).

Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.

Fri, 27 Jan 2012 10:24:00 +0100

Nat Rev Clin Oncol. 2012 Jan 24. doi: 10.1038/nrclinonc.2012.1. [Epub ahead of print]
Torres HA, Davila M.
Department of Infectious Diseases, Infection Control and Employee Health, Unit 1460.

Infections with hepatitis B virus (HBV) or hepatitis C virus (HCV) are associated with significant morbidity and mortality among patients with cancer, especially in patients with hematologic malignancies and those who undergo hematopoietic stem-cell transplantation.

Reported rates of HBV reactivation in HBV carriers who undergo chemotherapy range from 14-72%. In these patients, mortality rates range from 5-52%. HCV reactivation seems to be less common than HBV reactivation

Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.

Fri, 27 Jan 2012 10:14:00 +0100

Antivir Ther. 2012;17(1):35-43.
Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Yatsuhashi H, Izumi N.
Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.

BACKGROUND:
This study aimed to define factors associated with relapse among responders to pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy in chronic hepatitis C.

METHODS:
A cohort of genotype 1b chronic hepatitis C patients treated with PEG-IFN plus RBV and who had an undetectable HCV RNA by week